Stockscreener 앱 받기
41.29
0.43%
-0.18
시장 영업 전:
40.10
-1.19
-2.88%
전일 마감가:
$41.47
열려 있는:
$41.5
하루 거래량:
1.61M
Relative Volume:
0.83
시가총액:
$4.88B
수익:
$1.29B
순이익/손실:
$251.00M
주가수익비율:
20.91
EPS:
1.9744
순현금흐름:
$-193.86M
1주 성능:
+7.81%
1개월 성능:
+10.02%
6개월 성능:
+14.19%
1년 성능:
+200.73%
1일 변동 폭
$40.12
$42.07
1주일 범위
$37.64
$42.07
52주 변동 폭
$13.47
$42.07
Indivior Pharmaceuticals Inc Stock (INDV) Company Profile
명칭
Indivior Pharmaceuticals Inc
전화
804-379-1090
주소
10710 MIDLOTHIAN TURNPIKE, NORTH CHESTERFIELD
Compare INDV vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INDV
Indivior Pharmaceuticals Inc
|
41.29 | 4.90B | 1.29B | 251.00M | -193.86M | 1.9744 |
TAK
Takeda Pharmaceutical Co Adr
|
15.65 | 49.67B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.27 | 40.68B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.62 | 39.85B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
77.82 | 32.77B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
543.39 | 23.34B | 3.17B | 1.29B | 1.01B | 27.09 |
Indivior Pharmaceuticals Inc Stock (INDV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-06 | 개시 | H.C. Wainwright | Buy |
| 2025-07-22 | 재개 | Jefferies | Buy |
| 2025-01-28 | 개시 | Rodman & Renshaw | Buy |
| 2024-07-23 | 개시 | Piper Sandler | Overweight |
| 2024-04-03 | 개시 | Craig Hallum | Buy |
| 2023-07-13 | 개시 | Northland Capital | Outperform |
모두보기
Indivior Pharmaceuticals Inc 주식(INDV)의 최신 뉴스
Price to earnings forward of Indivior Pharmaceuticals, Inc. – BMV:INDV1 - TradingView
IBD 50 stock Indivior breaks out amid big fund ownership expansion, strong profit prospects - MSN
E7P Forecast — Price Target — Prediction for 2027 - TradingView
Reasons Why Investors Should Consider Betting on Indivior Stock - TradingView
Form 4 Indivior PLC For: 23 June By Investing.com - Investing.com Canada
Indivior Pharmaceuticals (INDV) CEO vests 1.27M shares, 612K for taxes - Stock Titan
Indivior gains new overweight at Barclays on business turnaround - MSN
Does Indivior Pharmaceuticals Inc. (INDV) have the potential to rally 32.48% as Wall Street analysts expect? - MSN
Indivior Pharmaceuticals (INDV) Stock Could Be 23% Undervalued As Cost Cut Narrative Builds - Sahm
INDV News | INDIVIOR PHARMACEUTICALS INC (NASDAQ:INDV) - ChartMill
INDIVIOR PHARMACEUTICALS INC (INDV) Stock Chart - ChartMill
Indivior stock gains new Overweight at Barclays (INDV:NASDAQ) - Seeking Alpha
Barclays Initiates Indivior at Overweight With $46 Price Target - marketscreener.com
Indivior PLC (INDV) Institutional Confidence - TradingKey
Indivior PLC (INDV) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
How Investors Are Reacting To Indivior (INDV) Upgraded 2026 Outlook And $175 Million Buyback Plan - Yahoo Finance
How Strong SUBLOCADE Uptake And A $175M Buyback At Indivior (INDV) Has Changed Its Investment Story - Sahm
Suboxone Tooth Decay Lawsuit Settlement June 2026 Update - Lawsuit Information Center
Indivior's Chief Scientific Officer Sold Over 18,000 Company Shares. Should Investors Worry? - Yahoo Finance
Is Indivior Pharmaceuticals, Inc. (INDV) A Good Stock To Buy Now? - Insider Monkey
Recent price trend in Indivior Pharmaceuticals Inc. (INDV) is your friend, here's why - MSN
Indivior Pharmaceuticals Inc (INDV) Insider Sell: Christian Heid - GuruFocus
Indivior (INDV) Chief Scientific Officer sells 18,586 shares under 10b5-1 plan - Stock Titan
INDV Stock: What Sublocade Growth Signals for 2026 - The Globe and Mail
INDV and the Shift to Long-Acting Opioid Use Disorder Care in 2026 - Yahoo Finance
Is Indivior Stock a Buy After Higher 2026 Guidance? - Yahoo Finance
Immunovant Stock Gains 12.4% in a Month: What's Driving It? - TradingView
GSK's Momelotinib Gets Orphan Tag for Rare Hemato-Inflammatory Disorder - TradingView
Indivior Pharmaceuticals Inc. (INDV) is a great momentum stock: Should you buy? - MSN
HROW Stock Rises on Relaunch of Ophthalmology Drug Verkazia in the US - The Globe and Mail
[144] Indivior Pharmaceuticals, Inc. SEC Filing - Stock Titan
A Look At Indivior Pharmaceuticals (INDV) Valuation After Strong Multi Period Share Price Gains - Yahoo Finance
Indivior CFO Ryan Preblick sells $1.36m in company stock By Investing.com - Investing.com Australia
Indivior Pharmaceuticals Inc (INDV) CFO Ryan Preblick Sells 36,0 - GuruFocus
Sanofi Ends Late-Stage Study on Neurology Drug Over Weak Results - TradingView
Indivior CFO Ryan Preblick sells $1.36m in company stock - Investing.com
Indivior Pharmaceuticals Insider Sold Shares Worth $1,357,200, According to a Recent SEC Filing - Moomoo
[Form 4] Indivior Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Indivior: A Stronger Business Than When I First Covered It (NASDAQ:INDV) - Seeking Alpha
Amended Form 144: INDV (NASDAQ: INDV) lists 36,000-share sale via Fidelity - Stock Titan
INDV (NASDAQ) proposes sale of 36,000 shares; $1.36M aggregate listed - Stock Titan
These healthcare stocks have maintained strong buy ratings for months - MSN
Indivior Pharmaceuticals, Inc. Statistics – LSX:A42086 - TradingView
Indivior (INDV) Hovers Near Resistance Amid Modest Gains – Key Levels in FocusOrder Block - newsline.com
Indivior Pharmaceuticals (INDV) Holds Steady Near Key Support Amidst Cautious TradingIchimoku Entry - newsline.com
Operating expenses (excl. COGS) of Indivior Pharmaceuticals, Inc. – XETR:E7P - TradingView
ALVO Stock Gains 19% on FDA Resubmission of Biosimilar BLAs - TradingView
Indivior PLC stock (GB00BYZ0C031): shares trade quietly as investors focus on valuation metrics - AD HOC NEWS
INDV Technical Analysis | Trend, Signals & Chart Patterns | INDIVIOR PHARMACEUTICALS INC (NASDAQ:INDV) - ChartMill
Indivior Pharmaceuticals Inc (INDV) Stock Up 5.1% but GF Value S - GuruFocus
Indivior Pharmaceuticals Inc (INDV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.72%
1.13%
자본화:
|
볼륨(24시간):